Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Daiichi Sankyo
UBS
McKinsey
Harvard Business School
Deloitte
Argus Health
Johnson and Johnson
Queensland Health
Accenture

Generated: February 21, 2018

DrugPatentWatch Database Preview

Pimavanserin tartrate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for pimavanserin tartrate and what is the scope of pimavanserin tartrate freedom to operate?

Pimavanserin tartrate
is the generic ingredient in one branded drug marketed by Acadia Pharms Inc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pimavanserin tartrate has one hundred and forty-two patent family members in twenty-seven countries.

One supplier is listed for this compound.
Summary for pimavanserin tartrate
International Patents:142
US Patents:14
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 67
Clinical Trials: 154
Patent Applications: 105
Drug Prices:see low prices
DailyMed Link:pimavanserin tartrate at DailyMed
Pharmacology for pimavanserin tartrate

US Patents and Regulatory Information for pimavanserin tartrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for pimavanserin tartrate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,713,995 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Sign Up
8,008,323 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Sign Up
2,017,165,273 ➤ Sign Up
7,790,899 Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)ph- enylmethyl)carbamide and its tartrate salt and crystalline forms ➤ Sign Up
8,227,487 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Sign Up
9,211,289 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Sign Up
7,868,176 Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N'-(4-(2-methylprop- yloxy)phenylmethyl)carbamide and their preparation ➤ Sign Up
8,236,960 Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms ➤ Sign Up
8,377,959 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Sign Up
7,393,861 Derivatives of 4-aminopiperidine and their use as a medicament ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for pimavanserin tartrate

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cerilliant
AstraZeneca
Harvard Business School
Mallinckrodt
Fuji
Farmers Insurance
Johnson and Johnson
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot